(Q35634609)

9 August 2017

1 reference

title

Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib (English)

1 reference

9 August 2017

1 reference

Gunhild Mechtersheimer

1

1 reference

9 August 2017

Gerlinde Egerer

2

1 reference

9 August 2017

Manfred Hensel

3

1 reference

9 August 2017

Ralf J Rieker

4

1 reference

9 August 2017

Martin Libicher

5

1 reference

9 August 2017

Thomas Lehnert

6

1 reference

9 August 2017

Roland Penzel

7

1 reference

9 August 2017

language of work or name

1 reference

20 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

444

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

108-118

1 reference

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

9 August 2017

cites work

1 reference

12 December 2020

Cell signaling by receptor tyrosine kinases

1 reference

12 December 2020

Class III receptor tyrosine kinases: role in leukaemogenesis

1 reference

12 December 2020

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

12 December 2020

Specific targeted therapy of chronic myelogenous leukemia with imatinib

1 reference

12 December 2020

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

1 reference

12 December 2020

Oncogenic kinase signalling

1 reference

12 December 2020

Protein tyrosine kinase structure and function

1 reference

12 December 2020

Identification of a ligand for the c-kit proto-oncogene

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

VEGF expression by epithelial and stromal cell compartments: resolving a controversy

1 reference

12 December 2020

Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).

1 reference

12 December 2020

Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment

1 reference

12 December 2020

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors

1 reference

12 December 2020

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

1 reference

12 December 2020

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

1 reference

12 December 2020

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

1 reference

12 December 2020

c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant

1 reference

12 December 2020

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

1 reference

12 December 2020

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

1 reference

12 December 2020

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies

1 reference

12 December 2020

Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal

1 reference

12 December 2020

Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity

1 reference

12 December 2020

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors

1 reference

12 December 2020

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

1 reference

12 December 2020

Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.

1 reference

12 December 2020

Alterations of the c-kit gene in testicular germ cell tumors

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene

1 reference

12 December 2020

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

1 reference

12 December 2020

Involvement of platelet-derived growth factor in disease: development of specific antagonists

1 reference

12 December 2020

Receptor tyrosine kinases as targets for anticancer drugs

1 reference

12 December 2020

Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

1 reference

12 December 2020

Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation.

1 reference

12 December 2020

C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.

1 reference

12 December 2020

Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan

1 reference

12 December 2020

Activating c-kit gene mutations in human germ cell tumors

1 reference

12 December 2020

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.

1 reference

12 December 2020

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

12 December 2020

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

12 December 2020

CD117 (KIT): a diverse protein with selective applications in surgical pathology

1 reference

12 December 2020

The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).

1 reference

12 December 2020

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

12 December 2020

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

1 reference

12 December 2020

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

1 reference

12 December 2020

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Advances in Molecular Therapies in Patients with Brain Tumors

1 reference

12 December 2020

10.1007/S00428-003-0945-5

Identifiers

DOI

1 reference

9 August 2017

1 reference